Sarcopenia, H1 2020 - Armgo Pharma Inc, Elevian Inc, Immusoft Corp, Neurotune AG & Ridgeline Therapeutics LLC - ResearchAndMarkets.com

The "Sarcopenia - Pipeline Review, H1 2020" report has been added to ResearchAndMarkets.com's offering.

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H1 2020, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

Sarcopenia is an aging-associated condition which is characterized by loss of muscle mass, strength and function. Symptoms include weakness, loss of endurance and poor balance. Causes of sarcopenia include a reduction in the nerve cells, low hormone levels and decline in body's ability to convert protein to energy. Treatment includes hormone replacement therapy (HRT), exercise and dietary supplements.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Sarcopenia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 13, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Report Coverage
• Sarcopenia - Overview
• Sarcopenia - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Sarcopenia - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Sarcopenia - Companies Involved in Therapeutics Development
• AAVogen Inc
• Armgo Pharma Inc
• Biophytis SA
• Elevian Inc
• Faraday Pharmaceuticals Inc
• Gerologix Inc
• Helixmith Co Ltd
• Immusoft Corp
• Keren Therapeutics
• MYOS RENS Technology Inc
• Neurotune AG
• Oncocross Co Ltd
• OPKO Health Inc
• PhaseBio Pharmaceuticals Inc
• Rejuvenate Biomed NV
• Ridgeline Therapeutics LLC
• ST Pharm Co Ltd
• Teijin Pharma Ltd
• Sarcopenia - Drug Profiles
• ARM-210 - Drug Profile
• AVGN-7 - Drug Profile
• Sarcopenia - Dormant Projects
• Sarcopenia - Discontinued Products
• Sarcopenia - Product Development Milestones
• Featured News & Press Releases
• Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ozcd5l

View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005537/en/